This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Braunstein, I. Articles by Skorecki, K. L. Search for Related Content PubMed PubMed Citation Articles by Braunstein, I. Articles by Skorecki, K. L.

Human Telomerase Reverse Transcriptase Promoter Regulation in Normal and Malignant Human Ovarian Epithelial Cells¹

Bruce Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa 31096, Israel [I. B., C-B., C. S., M. Y-H., K. L. S.]; Laboratory of Molecular Medicine, Department of Nephrology, Rambam Medical Center, Haifa 31096, Israel [Y. R., M. T., K. L. S.]; The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [G. B. M.]; and University of Arizona, Children’s Research Center, Tucson, Arizona 85724 [O. C-B.]

The telomerase RNA-protein complex responsible for maintenance of telomeric DNA at chromosome ends, is usually inactive in most primary somatic human cells, but is specifically activated with in vitro immortalization and during tumorigenesis. Although expression of the RNA component of telomerase appears to be constitutive, the expression pattern of human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase, is correlated with measured enzyme activity. In particular, a >80% concordance has been reported between telomerase activity and hTERT mRNA expression in ovarian tumors. Accordingly, to learn more about the mechanism regulating hTERT gene expression in ovarian carcinoma, we have performed a detailed analysis of the 5'-flanking promoter region of the hTERT gene. We have reported previously the isolation and analysis of a 5.8-kb genomic fragment containing the human hTERT gene promoter (M. Tzukerman et al., Mol. Biol. Cell, 11: 4381–4391, 2000). Deletion analysis of this promoter was carried out using transient transfection of promoter-reporter constructs in four different telomerase-expressing, ovarian carcinoma-derived cell lines, the tumorigenic properties of which have been characterized, and was compared with telomerase-negative primary human fibroblasts and nontransformed ovarian epithelial cells. These assays have shown that the hTERT promoter is inactive in telomerase-negative cells and is active in telomerase-positive cell lines. A core promoter of 283 bp upstream of the transcription initiation site (TI) was found to be sufficient for maximum promoter activity, suggesting the presence of inhibitory elements within the larger promoter sequence. Gel shift analysis of the core promoter using nuclear extracts from the ovarian and control cell lines revealed specific transcription factor binding using extracts from telomerase-positive cells.

Among the binding elements, we identified two E-boxes (CACGTG) as well as a novel element (MT-box), which we identified recently in a number of differentiation systems. Site-directed mutagenesis was used to introduce mutations into this novel transcription factor binding element. These mutations significantly affect the transcriptional activity of hTERT promoter in a cell type-specific manner and suggest that the transcription factors that bind to the E-box and the novel element cooperatively function as major determinants of hTERT expression and telomerase activity in ovarian cancer. Further comparison of promoter activity, telomerase activity, and telomere length among the different ovarian cancer cells indicated that a threshold level of telomerase activity is apparently sufficient to protect telomere integrity and permit the immortal state of the different ovarian cancer cell lines.

This article has been cited by other articles:

				X. Xie, J. L. Hsu, M.-G. Choi, W. Xia, H. Yamaguchi, C.-T. Chen, B. Q. Trinh, Z. Lu, N. T. Ueno, J. K. Wolf, et al. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer Mol. Cancer Ther., August 1, 2009; 8(8): 2375 - 2382. [Abstract] [Full Text] [PDF]

				S. Yehezkel, Y. Segev, E. Viegas-Pequignot, K. Skorecki, and S. Selig Hypomethylation of subtelomeric regions in ICF syndrome is associated with abnormally short telomeres and enhanced transcription from telomeric regions Hum. Mol. Genet., September 15, 2008; 17(18): 2776 - 2789. [Abstract] [Full Text] [PDF]

				L. G. Wooten and B. Ogretmen Sp1/Sp3-dependent Regulation of Human Telomerase Reverse Transcriptase Promoter Activity by the Bioactive Sphingolipid Ceramide J. Biol. Chem., August 12, 2005; 280(32): 28867 - 28876. [Abstract] [Full Text] [PDF]

				Y. Matsumura-Arioka, K. Ohtani, T. Hara, R. Iwanaga, and M. Nakamura Identification of two distinct elements mediating activation of telomerase (hTERT) gene expression in association with cell growth in human T cells Int. Immunol., February 1, 2005; 17(2): 207 - 215. [Abstract] [Full Text] [PDF]

				F. Jiang, J. Bao, P. Li, S. V. Nicosia, and W. Bai Induction of Ovarian Cancer Cell Apoptosis by 1,25-Dihydroxyvitamin D3 through the Down-regulation of Telomerase J. Biol. Chem., December 17, 2004; 279(51): 53213 - 53221. [Abstract] [Full Text] [PDF]

				I. Shats, M. Milyavsky, X. Tang, P. Stambolsky, N. Erez, R. Brosh, I. Kogan, I. Braunstein, M. Tzukerman, D. Ginsberg, et al. p53-dependent Down-regulation of Telomerase Is Mediated by p21waf1 J. Biol. Chem., December 3, 2004; 279(49): 50976 - 50985. [Abstract] [Full Text] [PDF]

				M. Yalon, S. Gal, Y. Segev, S. Selig, and K. L. Skorecki Sister chromatid separation at human telomeric regions J. Cell Sci., April 15, 2004; 117(10): 1961 - 1970. [Abstract] [Full Text] [PDF]

				M. Tzukerman, T. Rosenberg, Y. Ravel, I. Reiter, R. Coleman, and K. Skorecki An experimental platform for studying growth and invasiveness of tumor cells within teratomas derived from human embryonic stem cells PNAS, November 11, 2003; 100(23): 13507 - 13512. [Abstract] [Full Text] [PDF]

				I. Horikawa and J. C. Barrett Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms Carcinogenesis, July 1, 2003; 24(7): 1167 - 1176. [Abstract] [Full Text] [PDF]

				H. Szutorisz, J. Lingner, A. P. Cuthbert, D. A. Trott, R. F. Newbold, and M. Nabholz A Chromosome 3-encoded Repressor of the Human Telomerase Reverse Transcriptase (hTERT) Gene Controls the State of hTERT Chromatin Cancer Res., February 1, 2003; 63(3): 689 - 695. [Abstract] [Full Text] [PDF]

				A. Tomassetti, F. Mangiarotti, M. Mazzi, S. Sforzini, S. Miotti, E. Galmozzi, P. C. Elwood, and S. Canevari The Variant Hepatocyte Nuclear Factor 1 Activates the P1 Promoter of the Human {alpha}-Folate Receptor Gene in Ovarian Carcinoma Cancer Res., February 1, 2003; 63(3): 696 - 704. [Abstract] [Full Text] [PDF]

				D. J. Argyle and L. Nasir Telomerase: A Potential Diagnostic and Therapeutic Tool in Canine Oncology Veterinary Pathology, January 1, 2003; 40(1): 1 - 7. [Abstract] [Full Text] [PDF]

				A. Lev, G. Denkberg, C. J. Cohen, M. Tzukerman, K. L. Skorecki, P. Chames, H. R. Hoogenboom, and Y. Reiter Isolation and Characterization of Human Recombinant Antibodies Endowed with the Antigen-specific, Major Histocompatibility Complex-restricted Specificity of T Cells Directed toward the Widely Expressed Tumor T-cell Epitopes of the Telomerase Catalytic Subunit Cancer Res., June 1, 2002; 62(11): 3184 - 3194. [Abstract] [Full Text] [PDF]